{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:59:56Z","timestamp":1780693196727,"version":"3.54.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>We report an unusual imaging finding on DOTATATE PET\/CT in a patient with prior 177Lu-DOTATATE treatment for metastatic small bowel neuroendocrine tumor. Five years post-treatment follow-up DOTATATE PET\/CT for fatigue and back pain showed new diffusely increased bone marrow uptake in addition to focal uptake corresponding to known metastases. Faint\/mild bone marrow uptake of DOTATATE can be seen due to the presence of SST-2 receptor on CD-34 hematopoietic progenitor cells in the marrow, but diffusely increased marrow uptake, as in this case, was not deemed physiologic and was concerning for marrow pathology. Subsequent bone marrow biopsy confirmed therapy-related myelodysplastic syndrome (t-MDS).<\/jats:p>","DOI":"10.1097\/rlu.0000000000006095","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:00:32Z","timestamp":1755666032000},"page":"e475-e477","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Diffusely Increased Bone Marrow Uptake on DOTATATE PET\/CT Due to PRRT-related Myelodysplasia Syndrome"],"prefix":"10.1097","volume":"51","author":[{"given":"Chenxi","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Menshikova","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol M.","family":"Takalkar","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","article-title":"Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma","volume":"2","author":"Swisher","year":"2016","journal-title":"JAMA Oncol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","article-title":"Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival","volume":"48","author":"Chantadisai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/RLU.0000000000004386","article-title":"68Ga-DOTATATE PET\/CT incidentally detects relapsed chronic lymphocytic leukemia in patient with metastatic neuroendocrine tumor","volume":"48","author":"Alabed","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","article-title":"Specific uptake in the bone marrow causes high absorbed red marrow doses during [(177)Lu]Lu-DOTATATE treatment","volume":"64","author":"Hemmingsson","year":"2023","journal-title":"J Nucl Med"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/RLU.0000000000005450","article-title":"68 Ga-DOTATATE and 18 F-FDG PET\/CT in a rapidly progressing lymphoma","volume":"50","author":"Parihar","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"(68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/RLU.0000000000000282","article-title":"(68)Ga DOTATATE uptake in vertebral hemangioma","volume":"39","author":"Brogsitter","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/RLU.0000000000001065","article-title":"Schmorl nodes can cause increased 68Ga DOTATATE activity on PET\/CT, mimicking metastasis in patients with neuroendocrine malignancy","volume":"41","author":"Papadakis","year":"2016","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:29Z","timestamp":1780689629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006095","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}